On Aug. 10, 2020, iBio provided an update on one of its proprietary vaccine candidates being designed to prevent infection from the SARS-CoV-2 virus. Ten distinct preclinical study arms for the IBIO-201 antigen-adjuvant combinations have been concluded.

Early functional testing of mouse antisera from IBIO-201 immunized mice demonstrates the presence of antibodies that interfere with the binding of SARS-CoV-2 spike protein sequences to human ACE2 in ex vivo assays.